Published in Gastroenterology on July 01, 2003
Timing and Duration of Acute Hepatitis C Treatment | NCT00241618
Treating viral hepatitis C: efficacy, side effects, and complications. Gut (2006) 3.71
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis (2009) 2.82
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis (2009) 2.68
Genetic history of hepatitis C virus in East Asia. J Virol (2008) 2.20
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology (2009) 2.10
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Hepatitis C. Lancet (2015) 1.95
Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol (2007) 1.89
Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80
Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat (2009) 1.75
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis (2012) 1.66
Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis (2009) 1.49
Spontaneous clearance of hepatitis C virus in vertically infected children. Eur J Pediatr (2011) 1.47
Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology (2014) 1.46
Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol (2007) 1.44
Outcome of a hepatitis C outbreak among patients in a pain management clinic. Dig Dis Sci (2010) 1.43
Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut (2004) 1.42
Progress on new vaccine strategies against chronic viral infections. J Clin Invest (2004) 1.38
Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38
An overview of HCV molecular biology, replication and immune responses. Virol J (2011) 1.37
Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr (2006) 1.32
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med (2013) 1.28
New insights into acute hepatitis C. Gastroenterology (2003) 1.18
Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther (2013) 1.15
Temporal variations in the hepatitis C virus intrahost population during chronic infection. J Virol (2011) 1.15
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One (2012) 1.09
Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol (2006) 1.08
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology (2012) 1.07
Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk. AIDS Patient Care STDS (2011) 1.05
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis (2016) 1.01
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend (2010) 1.01
Current status and future directions in the management of chronic hepatitis C. Virol J (2012) 0.99
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood (2007) 0.98
Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J (2007) 0.97
Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology (2011) 0.97
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis (2012) 0.95
Early detection of hepatitis C virus infection by use of a new combined antigen-antibody detection assay: potential use for high-risk individuals. J Clin Microbiol (2006) 0.95
The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol (2004) 0.95
The seroprevalence of hepatitis C virus (HCV) among 559,890 first-time volunteer blood donors in China reflects regional heterogeneity in HCV prevalence and changes in blood donor recruitment models. Transfusion (2010) 0.94
Hepatitis C: a clinical review. Oral Dis (2008) 0.94
Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy. J Virol (2011) 0.92
Prospective follow-up of patients with acute hepatitis C virus infection in Brazil. Clin Infect Dis (2010) 0.92
Investigation of Transforming Growth Factor-β1 Gene Polymorphisms Among Iranian Patients With Chronic Hepatitis C. Hepat Mon (2011) 0.91
Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates. World J Gastroenterol (2007) 0.91
Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine (2010) 0.91
Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther Adv Chronic Dis (2011) 0.91
A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME). Transfusion (2010) 0.90
Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis (2012) 0.90
Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int (2011) 0.90
The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study. Hepat Mon (2014) 0.90
Hepatitis C virus prevalence and genotype distribution in Pakistan: Comprehensive review of recent data. World J Gastroenterol (2016) 0.88
Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses (2010) 0.87
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
The impact of illicit drug use on spontaneous hepatitis C clearance: experience from a large cohort population study. PLoS One (2011) 0.87
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS (2012) 0.84
Clinical characteristics, spontaneous clearance and treatment outcome of acute hepatitis C: a single tertiary center experience. Saudi J Gastroenterol (2013) 0.84
Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a. PLoS One (2008) 0.84
Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunol (2010) 0.84
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence (2013) 0.83
Current therapy for hepatitis C. Int J Colorectal Dis (2005) 0.83
Sustained viral response of a case of acute hepatitis C virus infection via needle-stick injury. World J Gastroenterol (2006) 0.83
Glances in Immunology of HIV and HCV Infection. Adv Virol (2012) 0.82
Analysis of the virus dynamics model reveals that early treatment of HCV infection may lead to the sustained virological response. PLoS One (2012) 0.82
Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept. Eur J Med Res (2011) 0.82
Transmission of hepatitis C virus: self-limiting hepatitis or chronic hepatitis? World J Gastroenterol (2013) 0.81
Acute hepatitis C in an HIV-infected patient: a case report and review of literature. J Gen Intern Med (2012) 0.81
Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b. PLoS One (2014) 0.81
Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol (2016) 0.81
Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C. Clin Infect Dis (2013) 0.81
SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80
Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil. BMC Infect Dis (2011) 0.80
Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers. Infect Control Hosp Epidemiol (2009) 0.79
Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci (2014) 0.79
Spontaneous viral clearance of hepatitis C virus (HCV) infection among people who inject drugs (PWID) and HIV-positive men who have sex with men (HIV+ MSM): a systematic review and meta-analysis. BMC Infect Dis (2016) 0.79
Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection. BMJ Open (2012) 0.78
Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol (2014) 0.78
Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment. J Gastroenterol Hepatol (2013) 0.78
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol (2015) 0.78
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. PLoS One (2015) 0.77
Hepatitis C genotype 4: The past, present, and future. World J Hepatol (2015) 0.77
Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy. PLoS One (2016) 0.77
Making the best of a bad situation: early chronic nosocomial HCV infection. Dig Dis Sci (2010) 0.77
Distinct features in natural history and outcomes of acute hepatitis C. J Clin Gastroenterol (2015) 0.76
Between Scylla and Charybdis: the role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol (2013) 0.76
Predictors of spontaneous viral clearance and outcomes of acute hepatitis C infection. Clin Mol Hepatol (2014) 0.75
Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection. Gastroenterology Res (2013) 0.75
Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infect Dis (Lond) (2015) 0.75
Acute hepatitis C virus infection: to treat or not to treat? Gastroenterology (2004) 0.75
New tools in HCV diagnosis, in light of the enhanced awareness and the new drugs for treatment: SMARTube and stimmunology. ScientificWorldJournal (2013) 0.75
Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing. Clin Infect Dis (2016) 0.75
Adaptive immunity to hepatitis C virus. Viruses (2009) 0.75
Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol (2015) 0.75
Validation of EGCRISC for Chronic Hepatitis C Infection Screening and Risk Assessment in the Egyptian Population. PLoS One (2016) 0.75
Interferon Lambda 4 Genotype Is Associated With Jaundice and Elevated Aminotransferase Levels During Acute Hepatitis C Virus Infection: Findings From the InC3 Collaborative. Open Forum Infect Dis (2016) 0.75
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Immunology of hepatitis B infection. Lancet Infect Dis (2002) 1.75
Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology (2003) 1.52
The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology (2010) 1.48
Opioid detoxification with delta sleep-inducing peptide: results of an open clinical trial. J Clin Psychopharmacol (1998) 1.38
Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology (2005) 1.33
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology (2007) 1.32
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
SOCS-1 and SOCS-3 inhibit IFN-alpha-induced expression of the antiviral proteins 2,5-OAS and MxA. Biochem Biophys Res Commun (2004) 1.27
Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One (2010) 1.26
Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol (2003) 1.23
The role of interleukin-22 in hepatitis C virus infection. Cytokine (2008) 1.20
Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis (2005) 1.18
Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci (2006) 1.16
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
Recurrent hepatitis C virus infection after liver transplantation: natural course, therapeutic approach and possible mechanisms of viral control. J Antimicrob Chemother (2004) 1.14
Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood (2005) 1.11
Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol (2008) 1.09
A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-alpha. J Immunol (2003) 1.03
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology (2003) 1.00
Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology (2011) 0.96
Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther (2013) 0.96
FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology (2009) 0.91
Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PLoS One (2013) 0.91
Psychiatric and psychosocial outcome of orthotopic liver transplantation. Psychother Psychosom (2002) 0.88
Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J Hepatol (2002) 0.87
Antibody responses against B-cell epitopes of the hypervariable region 1 of hepatitis C virus in self-limiting and chronic human hepatitis C followed-up using consensus peptides. J Med Virol (2002) 0.86
Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS One (2011) 0.86
Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: results from a nationwide non-interventional study in routine care. Pharmacopsychiatry (2013) 0.84
YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol (2011) 0.84
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? Hepatology (2004) 0.83
Of chimps and men--finding the path to an HCV vaccine. Hepatology (2003) 0.81
Acute pancreatitis and pericardial effusion in Behçet's disease. Gastroenterology (1999) 0.80
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. Eur J Gastroenterol Hepatol (2007) 0.79
Successful treatment of acute liver failure due to polyarteritis nodosa. Am J Med (2002) 0.79
Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients. Liver Transpl (2006) 0.79
Insulin-like growth factors and insulin-like growth factor binding proteins in adult patients with severe liver disease before and after orthotopic liver transplantation. Horm Res (2002) 0.78
Interferon-alpha for hepatitis C: antiviral or immunotherapy? J Hepatol (2004) 0.78
Analysis of a successful HCV-specific CD8+ T cell response in patients with recurrent HCV-infection after orthotopic liver transplantation. Liver Transpl (2004) 0.78
Tramadol use and dependence in chronic noncancer pain patients. Pharmacopsychiatry (2004) 0.78
Late appearance of hepatitis C virus RNA after needlestick injury: necessity for a more intensive follow-up. Infect Control Hosp Epidemiol (2009) 0.77
The role of graft-resident Kupffer cells and lymphocytes of donor type during the time course after liver transplantation--a clinico-pathological study. Virchows Arch (2003) 0.77
Acute liver failure, rupture and hemorrhagic shock as primary manifestation of advanced metastatic disease. Anticancer Res (2012) 0.77
Depression during therapy with interferon alpha--how long should an antidepressant treatment last? Pharmacopsychiatry (2005) 0.77
Lack of variant specific CD8+ T-cell response against mutant and pre-existing variants leads to outgrowth of particular clones in acute hepatitis C. Virol J (2013) 0.77
Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12. Eur J Gastroenterol Hepatol (2008) 0.76
Clearance of HBV markers and HCC risk: who is safe? Gut (2014) 0.76
Dieting influences the menstrual cycle: vegetarian versus nonvegetarian diet. Fertil Steril (1986) 0.76
Antiviral treatment of recurrent hepatitis C virus (HCV) infection after liver transplantation: association of a strong, multispecific, and long-lasting CD4+ T cell response with HCV-elimination. J Hepatol (2003) 0.76
Recurrence of hepatitis C virus during leucocytopenia and spontaneous clearance after recovery from cytopenia: a case report. J Med Case Rep (2007) 0.75
Dialyzable free cortisol after stimulation with Synacthen. Clin Biochem (2002) 0.75
Psychomotor disturbances in psychiatric patients as a possible basis for new attempts at differential diagnosis and therapy. IV. Brain dysfunction during motor activation measured by EEG mapping. Eur Arch Psychiatry Neurol Sci (1989) 0.75
Can specific heterologous immunity boost hepatitis B vaccine responses? J Infect Dis (2008) 0.75
Characterization of sequence variations in immunodominant regions of the HBV-nucleocapsid protein as a prerequisite for the development of an epitope-based vaccine. Vaccine (2006) 0.75
Leucocytapheresis with Adacolumn enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1. J Med Virol (2005) 0.75